Enanta Pharmaceuticals, Inc. ENTA
11.88
(0.12)
(1.00%)
as of 25 Sep
- Market cap
- $349.5M
- P/E
- 0.0×
Follow ENTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (70.12%) | (59.00%) | (60.01%) | (84.63%) |
+8 more TTM periods Free account |
|
| (21.15%) | (19.44%) | (21.10%) | (24.91%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(34.86%) | (37.55%) | (38.00%) | (42.83%) | |
Average Days of Receivables |
36.55 | 41.28 | 46.28 | 38.45 | |
Free Cash Flow per Share |
(1.27) | (0.33) | (0.64) | (1.51) | |
Free Cash Flow |
(36.94) | (9.61) | (18.46) | (32.17) | |
Capital Expenditures |
(1.62) | (1.77) | (4.29) | (12.90) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(12.15%) | (2.80%) | (4.54%) | (7.60%) | |
Accounts Receivable Turnover |
8.76 | 2.86 | 2.75 | 2.87 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.02) | (0.02) | |
Research and Development Expense of Revenue |
132.15% | 131.94% | 149.21% | 163.40% | |
Selling, General and Administrative Expense of Revenue |
57.84% | 55.30% | 59.86% | 67.25% | |
Share Based Compensation of Revenue |
23.41% | 22.78% | 24.95% | 28.42% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.56 | 0.13 | 0.20 | 0.24 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.14 | 0.14 | |
Capex/Depreciation |
(0.38) | (0.41) | (0.89) | (2.53) | |
Revenue per Share |
2.24 | 2.38 | 2.33 | 3.06 | |
Operating CF per Share |
(1.21) | (0.27) | (0.49) | (0.90) | |
Capex per Share |
(0.06) | (0.06) | (0.15) | (0.60) | |
Capex to Sales |
0.02 | 0.03 | 0.06 | 0.20 | |
Net Profit Margin |
(96.89%) | (89.56%) | (106.80%) | (125.36%) |
Columns are period end dates